ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

Centers Can Collaborate Well with Industry, Albert LoBuglio Says

May 7, 1999

DRCCA Completes New Cancer control Research Guidelines

August 5, 1983

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Pittsburgh Investigates Use of Resources in Anonymous Mailing To Researchers

April 29, 1994

Paul Marks To Chair Search Committee For NCI Director

January 20, 1995

ODAC Votes 10-0 In Favor Of Avastin For Recurrent Glioblastoma Multiforme

April 3, 2009